NEW YORK--(BUSINESS WIRE)--

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (NASDAQ:OCUL) of the September 5, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Ocular stock or options between March 10, 2016 and July 11, 2017 and would like to discuss your legal rights, click here: www.faruqilaw.com/OCUL. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].

The lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all those who purchased Ocular securities between March 10, 2016 and July 11, 2017 (the “Class Period”). The case, Kim v. Ocular Therapeutix, Inc. et al, No. 2:17-cv-05704 was filed on August 3, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Ocular failed to adequately address the issues raised by the U.S. Food and Drug Administration (“FDA”) regarding the Company’s pain-relief drug, DEXTENZA; (2) the Company’s re-submitted New Drug Application would not be timely approved because the Company could not adequately address certain manufacturing and control issues associated with DEXTENZA; (3) Ocular’s continued manufacturing issues imperil the approval of DEXTENZA; and (4) as a result, the Company’s public statements were materially false and misleading.

Specifically, on July 6, 2017, an article released on Seeking Alpha claimed, in part, that the Company may have been misleading investors, including that more than 50% of lots manufactured by the Company contain bad product. On the same day, STAT published an article claiming that DEXTENZA could be rejected by the FDA because of product contamination found by an FDA inspector during a visit to the Company’s manufacturing facility.

On this news, Ocular’s share price fell from $10.18 per share on July 5, 2017 to a closing price of $6.49 on July 10, 2017—a $3.69 or a 36.25% drop.

Finally, on July 11, 2017, the Company issued a press release announcing that it had received a Complete Response Letter indicating that the FDA had determined it could not approve the application for DEXTENZA in its present form.

Following this news, Ocular’s share price fell from $7.60 per share on July 11, 2017 to a closing price of $6.67 on July 12, 2017—a $0.93 or a 12.24% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Ocular’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170825005667/en/